Skip to content

Efficacy, Safety and Cost Effectiveness of Four Therapeutic Agents for Treatment of Scabies

Efficacy, Safety and Cost Effectiveness of Four Therapeutic Agents for Treatment of Scabies

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR201505001116484
Enrollment
250
Registered
2015-04-25
Start date
2012-11-04
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin and Connective Tissue Diseases scabies

Interventions

Ivermectin
Sulfur ointment
Permethrin lotion
Benzyle Benzoate 20 percent cream

Sponsors

Faculty of medicine
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: scabies; patients experiencing itching that involved at least three distinct sites on the body and had lesions that were characteristic of scabies history of nocturnal itching history of involvment of family members history of contact with scabies pateint presence of classical burrows on clinical examination presence of typical scabietic lesions like,papules, nodules and vesicles either gender above 5years of age willing to participate

Exclusion criteria

Exclusion criteria: Pregnant or lactating women. Children 50 years old. body weight less than 15 kg. Participants had a general condition such as abnormal liver and kidney functions, known thyroid disease, cardiac disorders, nervous system disorder, and psychiatric illnesses. participants with history of diabetes mellitus, hypertension, or chronic infectious diseases. Participants with any other associated skin disease, which could alter the picture of scabies. immunocompromised individuals, having scabies with atypical presentations like crusted scabies. Participants who had taken any antiscabetic treatment in the preceding month.

Design outcomes

Primary

MeasureTime frame
complete absence of new lesions at the time of follow up and by negative parasitological examination of the patient

Secondary

MeasureTime frame
adverse drug reaction

Countries

Egypt

Contacts

Public ContactTalal Abdel-Raheem

Prof Dermatology, STD and Andrology, Faculty Medicine Univ Fayoum Egypt

talalsam@yahoo.com+201006600360

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026